Applied Therapeutics, Inc. (NASDAQ:APLT) Receives $6.10 Average Price Target from Brokerages

Applied Therapeutics, Inc. (NASDAQ:APLT) has received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.10.

Several equities analysts have issued reports on the company. Wall Street Zen upgraded Applied Therapeutics to a “sell” rating in a research note on Thursday, May 22nd. Royal Bank of Canada restated a “sector perform” rating and set a $1.50 price objective on shares of Applied Therapeutics in a report on Wednesday, May 14th.

Institutional Investors Weigh In On Applied Therapeutics

Large investors have recently bought and sold shares of the company. Ground Swell Capital LLC purchased a new stake in Applied Therapeutics in the fourth quarter valued at approximately $27,000. Toronto Dominion Bank purchased a new stake in Applied Therapeutics in the fourth quarter valued at approximately $27,000. Private Advisor Group LLC acquired a new position in shares of Applied Therapeutics in the 4th quarter valued at about $35,000. SG Americas Securities LLC lifted its holdings in shares of Applied Therapeutics by 169.0% in the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after buying an additional 25,601 shares during the period. Finally, CreativeOne Wealth LLC lifted its holdings in shares of Applied Therapeutics by 132.2% in the 1st quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company’s stock valued at $25,000 after buying an additional 28,701 shares during the period. Hedge funds and other institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Trading Down 2.3%

Shares of Applied Therapeutics stock opened at $0.39 on Friday. The stock’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.85. Applied Therapeutics has a 12 month low of $0.30 and a 12 month high of $10.62. The firm has a market cap of $54.66 million, a P/E ratio of -0.24 and a beta of 1.86.

Applied Therapeutics (NASDAQ:APLT) last posted its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.61 million. Analysts forecast that Applied Therapeutics will post -0.65 earnings per share for the current year.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.